Novavax (NVAX) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Novavax (NVAX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 6.22% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.23% |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn | 24.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.91% |
| Mar 31, 2026 | 53.65% |
| Dec 31, 2025 | 30.57% |
| Sep 30, 2025 | 68.50% |
| Jun 30, 2025 | 9.31% |
| Mar 31, 2025 | -27.97% |
| Dec 31, 2024 | 20.33% |
| Sep 30, 2024 | -0.62% |
| Jun 30, 2024 | 29.59% |
| Mar 31, 2024 | -28.58% |
| Dec 31, 2023 | -11.20% |
| Sep 30, 2023 | -82.75% |
| Jun 30, 2023 | -51.64% |
| Mar 31, 2023 | -141.52% |
| Dec 31, 2022 | -70.56% |
| Sep 30, 2022 | -6.26% |
| Jun 30, 2022 | -78.57% |
| Mar 31, 2022 | -20.48% |
| Dec 31, 2021 | -96.30% |
| Sep 30, 2021 | -61.87% |